Cardiovascular Diseases in COPD: From Diagnosis and Prevalence to Therapy
暂无分享,去创建一个
M. Idzko | D. Gompelmann | S. Loukides | A. Papaioannou | K. Bartziokas | P. Bakakos | A. Papaporfyriou | E. Fouka | Petros Bakakos | Stavrina Zaneli
[1] J. Varga,et al. Cardiovascular effects of exercise induced dynamic hyperinflation in COPD patients—Dynamically hyperinflated and non-hyperinflated subgroups , 2023, PloS one.
[2] Shuliang Guo,et al. Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis , 2022, European Respiratory Journal.
[3] D. Mannino,et al. Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for its Revision. , 2022, American journal of respiratory and critical care medicine.
[4] M. Newnham,et al. Cardiovascular disease in chronic obstructive pulmonary disease: a narrative review , 2022, Thorax.
[5] S. Bozinovski,et al. Chronic obstructive pulmonary disease and atherosclerosis: common mechanisms and novel therapeutics , 2022, Clinical science.
[6] Akshay S. Desai,et al. Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON‐HF , 2021, Journal of the American Heart Association.
[7] J. Wedzicha,et al. An Updated Definition and Severity Classification of COPD Exacerbations: The Rome Proposal. , 2021, American journal of respiratory and critical care medicine.
[8] R. Jackson,et al. Dual versus single long‐acting bronchodilator use could raise acute coronary syndrome risk by over 50%: A population‐based nested case–control study , 2021, Journal of internal medicine.
[9] M. Alexandrou,et al. Endothelial Dysfunction during Acute Exacerbations of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis , 2021, COPD.
[10] Jinghua Yang,et al. Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis , 2020, European heart journal.
[11] T. Martín Lorenzo,et al. Impact of non-cardiovascular comorbidities on the quality of life of patients with chronic heart failure: a scoping review , 2020, Health and Quality of Life Outcomes.
[12] P. Dorinsky,et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. , 2020, The New England journal of medicine.
[13] J. Díez-Manglano,et al. Management of the COPD Patient with Comorbidities: An Experts Recommendation Document , 2020, International journal of chronic obstructive pulmonary disease.
[14] Y. Mao,et al. Beta-blockers in COPD: A systematic review based on recent research. , 2020, Life sciences.
[15] J. Díez-Manglano,et al. Insights into Chronic Obstructive Pulmonary Disease as Critical Risk Factor for Cardiovascular Disease , 2020, International journal of chronic obstructive pulmonary disease.
[16] Y. Shyr,et al. Mortality of cardiovascular events in COPD patients with preceding hospitalized acute exacerbation. , 2020, Chest.
[17] Chung-Yu Chen,et al. Protective Effect of Statins on Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease Patients: A Nationwide Retrospective, Matched Cohort Study , 2020, Scientific Reports.
[18] A. Bottle,et al. Hospitalisation and mortality in patients with comorbid COPD and heart failure: a systematic review and meta-analysis , 2020, Respiratory Research.
[19] J. Hallas,et al. Increased risk of major adverse cardiac events following the onset of acute exacerbations of COPD , 2019, Respirology.
[20] J. Curtis,et al. Metoprolol for the Prevention of Acute Exacerbations of COPD. , 2019, The New England journal of medicine.
[21] H. Watz,et al. Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort , 2019, International journal of chronic obstructive pulmonary disease.
[22] E. McColl,et al. Antiplatelet therapy in the primary prevention of cardiovascular disease in patients with chronic obstructive pulmonary disease: a randomised controlled proof-of-concept trial , 2019, ERJ Open Research.
[23] Kuang-Yao Yang,et al. Real-world effectiveness of medications on survival in patients with COPD-heart failure overlap , 2019, Aging.
[24] S. Bozinovski,et al. New frontiers in the treatment of comorbid cardiovascular disease in chronic obstructive pulmonary disease , 2019, Clinical science.
[25] Meilan K. Han,et al. Aspirin Use and Respiratory Morbidity in COPD: A Propensity Score‐Matched Analysis in Subpopulations and Intermediate Outcome Measures in COPD Study , 2019, Chest.
[26] A. Khashan,et al. Statins versus placebo for people with chronic obstructive pulmonary disease. , 2019, The Cochrane database of systematic reviews.
[27] Mohammad Hossein Khosravi,et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, Lancet.
[28] Austin Carter,et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016–40 for 195 countries and territories , 2018, The Lancet.
[29] K. Rabe,et al. Cardiovascular disease and COPD: dangerous liaisons? , 2018, European Respiratory Review.
[30] L. Smeeth,et al. Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease , 2018, Annals of the American Thoracic Society.
[31] F. Martinez,et al. Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial , 2018, American journal of respiratory and critical care medicine.
[32] E. Lehman,et al. Preexisting Conditions Determine the Occurrence of Unplanned Readmissions after Procedures for Treatment of Peripheral Arterial Disease. , 2018, Annals of vascular surgery.
[33] Chong-Jen Yu,et al. Comparative effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD , 2018, International Journal of COPD.
[34] J. Quint,et al. Defining the relationship between COPD and CVD: what are the implications for clinical practice? , 2018, Therapeutic advances in respiratory disease.
[35] A. Mebazaa,et al. Characteristics, treatments and 1‐year prognosis of hospitalized and ambulatory heart failure patients with chronic obstructive pulmonary disease in the European Society of Cardiology Heart Failure Long‐Term Registry , 2018, European journal of heart failure.
[36] Eric A. Hoffman,et al. A Longitudinal Cohort Study of Aspirin Use and Progression of Emphysema‐like Lung Characteristics on CT Imaging: The MESA Lung Study , 2017, Chest.
[37] T. To,et al. Incident diuretic drug use and adverse respiratory events among older adults with chronic obstructive pulmonary disease , 2017, British journal of clinical pharmacology.
[38] Mph Tadahiro Goto MD,et al. Incidence of Acute Cardiovascular Event After Acute Exacerbation of COPD , 2018, Journal of General Internal Medicine.
[39] D. Kim,et al. Different impacts of respiratory symptoms and comorbidities on COPD-specific health-related quality of life by COPD severity , 2017, International journal of chronic obstructive pulmonary disease.
[40] K. Onishi. Total management of chronic obstructive pulmonary disease (COPD) as an independent risk factor for cardiovascular disease. , 2017, Journal of cardiology.
[41] S. Suissa,et al. Concurrent use of long-acting bronchodilators in COPD and the risk of adverse cardiovascular events , 2017, European Respiratory Journal.
[42] Megha A. Parikh,et al. Angiotensin‐Converting Inhibitors and Angiotensin II Receptor Blockers and Longitudinal Change in Percent Emphysema on Computed Tomography. The Multi‐Ethnic Study of Atherosclerosis Lung Study , 2017, Annals of the American Thoracic Society.
[43] R. Holle,et al. Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences‐Comorbidities Network Study , 2017, American journal of respiratory and critical care medicine.
[44] C. Butler,et al. Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study , 2017, BMJ Open.
[45] R. Wilcox,et al. β-Blockers, heart disease and COPD: current controversies and uncertainties , 2016, Thorax.
[46] D. Sin,et al. Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care. , 2016, American journal of respiratory and critical care medicine.
[47] O. Nishiyama,et al. Influence of comorbidities on the efficacy of pulmonary rehabilitation in patients with chronic obstructive pulmonary disease , 2016, Geriatrics & gerontology international.
[48] Volkmar Falk,et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.
[49] N. Tzanakis,et al. Acute exacerbation of COPD: is it the “stroke of the lungs”? , 2016, International journal of chronic obstructive pulmonary disease.
[50] R. Ferrari,et al. Antiplatelet Treatment Reduces All-Cause Mortality in COPD Patients: A Systematic Review and Meta-Analysis , 2016, COPD.
[51] M. Cazzola,et al. A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. , 2016, Chest.
[52] F. Martinez,et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial , 2016, The Lancet.
[53] J. Bourbeau,et al. Club Cell-16 and RelB as Novel Determinants of Arterial Stiffness in Exacerbating COPD Patients , 2016, PloS one.
[54] A. Hofman,et al. Chronic Obstructive Pulmonary Disease and the Risk of Stroke. The Rotterdam Study. , 2016, American journal of respiratory and critical care medicine.
[55] R. Hancox,et al. Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. , 2016, The Lancet. Respiratory medicine.
[56] N. Steen,et al. Validation of the DECAF score to predict hospital mortality in acute exacerbations of COPD , 2016, Thorax.
[57] S. Dias,et al. Efficacy and safety of long-acting β-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysis , 2015, Thorax.
[58] L. Ferder,et al. Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. , 2015, World journal of biological chemistry.
[59] N. Hansel,et al. Comorbidities and Chronic Obstructive Pulmonary Disease: Prevalence, Influence on Outcomes, and Management , 2015, Seminars in Respiratory and Critical Care Medicine.
[60] M. Sadatsafavi,et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. , 2015, The Lancet. Respiratory medicine.
[61] N. Scichilone,et al. Prevalence of Co-morbidities and Severity of COPD , 2015, COPD.
[62] M. Keltai,et al. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial , 2015, Journal of the American Heart Association.
[63] L. Smeeth,et al. Closing the mortality gap after a myocardial infarction in people with and without chronic obstructive pulmonary disease , 2015, Heart.
[64] G. Campo,et al. Chronic Obstructive Pulmonary Disease and Ischemic Heart Disease Comorbidity: Overview of Mechanisms and Clinical Management , 2015, Cardiovascular Drugs and Therapy.
[65] C. Gleissner,et al. Inflammatory therapeutic targets in coronary atherosclerosis—from molecular biology to clinical application , 2014, Front. Physiol..
[66] J. Bourbeau,et al. Alterations in the Expression of the NF-κB Family Member RelB as a Novel Marker of Cardiovascular Outcomes during Acute Exacerbations of Chronic Obstructive Pulmonary Disease , 2014, PloS one.
[67] J. Hallas,et al. Statin use and exacerbations in individuals with chronic obstructive pulmonary disease , 2014, Thorax.
[68] M. Decramer,et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. , 2014, The New England journal of medicine.
[69] Longhua Sun,et al. Decreased CD34+ cell number is correlated with cardiac dysfunction in patients with acute exacerbation of COPD. , 2014, Heart, lung & circulation.
[70] V. Menon,et al. Burden of cardiovascular disease in chronic obstructive pulmonary disease. , 2014, American journal of preventive medicine.
[71] A. Junqueira-Kipnis,et al. Interleukin-6 and interleukin-8 blood levels’ poor association with the severity and clinical profile of ex-smokers with COPD , 2014, International journal of chronic obstructive pulmonary disease.
[72] D. Sajkov,et al. Pulmonary Hypertension and Right Heart Dysfunction in Chronic Lung Disease , 2014, BioMed research international.
[73] C. Rihal,et al. Relation of chronic obstructive pulmonary disease to atrial and ventricular arrhythmias. , 2014, The American journal of cardiology.
[74] C. Gaudio,et al. Right Heart Functional Changes in the Acute, Hypercapnic Exacerbations of COPD , 2014, BioMed research international.
[75] Meilan K. Han,et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. , 2014, The New England journal of medicine.
[76] E. Ingelsson,et al. Differential association of chronic obstructive pulmonary disease with myocardial infarction and ischemic stroke in a nation-wide cohort. , 2014, International journal of cardiology.
[77] J. Pépin,et al. Arterial stiffness in COPD. , 2014, Chest.
[78] D. Matamis,et al. Targeting occult heart failure in intensive care unit patients with acute chronic obstructive pulmonary disease exacerbation: effect on outcome and quality of life. , 2014, Journal of critical care.
[79] P. Laveneziana,et al. Chronic obstructive pulmonary disease: clinical integrative physiology. , 2014, Clinics in chest medicine.
[80] J. Connett,et al. Club cell protein 16 and disease progression in chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.
[81] E. Wouters,et al. Arterial stiffness in patients with COPD: the role of systemic inflammation and the effects of pulmonary rehabilitation , 2013, European Respiratory Journal.
[82] W. Self,et al. Predictors of regional variations in hospitalizations following emergency department visits for atrial fibrillation. , 2013, The American journal of cardiology.
[83] A. Agustí,et al. Cardiovascular comorbidity in COPD: systematic literature review. , 2013, Chest.
[84] W. Paulus,et al. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. , 2013, Journal of the American College of Cardiology.
[85] T. Self,et al. The clinical and economic burden of chronic obstructive pulmonary disease in the USA , 2013, ClinicoEconomics and outcomes research : CEOR.
[86] M. Puhan,et al. Impact of co-morbidities on self-rated health in self-reported COPD: An analysis of NHANES 2001–2008 , 2013, COPD.
[87] D. Au,et al. Combination antihypertensive therapy among patients with COPD. , 2013, Chest.
[88] A. Akram,et al. Cardiovascular events after clarithromycin use in lower respiratory tract infections: analysis of two prospective cohort studies , 2013, BMJ.
[89] W. MacNee,et al. Cardiovascular disease in COPD: mechanisms. , 2013, Chest.
[90] M. Puhan,et al. Determinants of endothelial function in patients with COPD , 2013, European Respiratory Journal.
[91] M. Ekström,et al. Effects of cardiovascular drugs on mortality in severe chronic obstructive pulmonary disease. , 2013, American journal of respiratory and critical care medicine.
[92] B. Celli,et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. , 2012, American journal of respiratory and critical care medicine.
[93] J. Soriano,et al. Comorbidities and short-term prognosis in patients hospitalized for acute exacerbation of COPD: the EPOC en Servicios de medicina interna (ESMI) study. , 2012, Chest.
[94] John Steer,et al. The DECAF Score: predicting hospital mortality in exacerbations of chronic obstructive pulmonary disease , 2012, Thorax.
[95] S. Petersen,et al. Chronic obstructive pulmonary disease: a modifiable risk factor for cardiovascular disease? , 2012, Heart.
[96] G. Fonarow,et al. Clinical characteristics and outcomes of hospitalized heart failure patients with systolic dysfunction and chronic obstructive pulmonary disease: findings from OPTIMIZE‐HF , 2012, European journal of heart failure.
[97] J. Wedzicha,et al. The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. , 2012, Chest.
[98] B. Beghé,et al. Link between chronic obstructive pulmonary disease and coronary artery disease: Implication for clinical practice , 2012, Respirology.
[99] G. Lip,et al. Atrial fibrillation , 2012, The Lancet.
[100] D. Mapel. Insights into COPD Comorbidities from the OLIN Study and Other Large Databases , 2011, COPD.
[101] E. Clini,et al. Dynamic hyperinflation is associated with a poor cardiovascular response to exercise in COPD patients , 2011, Respiratory research.
[102] Anand A. Dalal,et al. Clinical and economic burden of patients diagnosed with COPD with comorbid cardiovascular disease. , 2011, Respiratory medicine.
[103] Olaf Holz,et al. Physical activity is the strongest predictor of all-cause mortality in patients with COPD: a prospective cohort study. , 2011, Chest.
[104] M. Decramer,et al. Risk of Nonlower Respiratory Serious Adverse Events Following COPD Exacerbations in the 4-year UPLIFT® Trial , 2011, Lung.
[105] L. Krakoff,et al. Glucocorticoids and cardiovascular risk factors. , 2011, Endocrinology and metabolism clinics of North America.
[106] Dong-Bin Kim,et al. Prognosis of heart failure patients with reduced and preserved ejection fraction and coexistent chronic obstructive pulmonary disease , 2010, European journal of heart failure.
[107] Joseph Lindsay,et al. Impact of chronic obstructive pulmonary disease on acute-phase outcome of myocardial infarction. , 2010, The American journal of cardiology.
[108] R. Stockley,et al. Systemic inflammation and comorbidity in COPD: a result of ‘overspill’ of inflammatory mediators from the lungs? Review of the evidence , 2010, Thorax.
[109] H. Magnussen,et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. , 2010, Chest.
[110] L. Ferreira,et al. Bronchodilators accelerate the dynamics of muscle O2 delivery and utilisation during exercise in COPD , 2010, Thorax.
[111] R. Hubbard,et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. , 2010, Chest.
[112] J. Soriano,et al. Comorbidity and gender-related differences in patients hospitalized for COPD. The ECCO study. , 2010, Respiratory medicine.
[113] A. Vonk-Noordegraaf. The shrinking heart in chronic obstructive pulmonary disease. , 2010, The New England journal of medicine.
[114] Y. Başaran,et al. Acute exacerbation impairs endothelial function in patients with chronic obstructive pulmonary disease. , 2010, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.
[115] R. Hopkins,et al. Pharmacological actions of statins: potential utility in COPD , 2009, European Respiratory Review.
[116] P. Almagro,et al. [Causes of mortality in COPD]. , 2009, Archivos de bronconeumologia.
[117] A. Valipour,et al. Determinants of systemic vascular function in patients with stable chronic obstructive pulmonary disease. , 2008, American journal of respiratory and critical care medicine.
[118] B. Celli,et al. Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD , 2008, European Respiratory Journal.
[119] D. Mannino,et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD , 2008, European Respiratory Journal.
[120] L. Edwards,et al. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort , 2008, Thorax.
[121] B. Make,et al. Comorbidities in chronic obstructive pulmonary disease. , 2008, Proceedings of the American Thoracic Society.
[122] G. Criner,et al. Cardiac disease in chronic obstructive pulmonary disease. , 2008, Proceedings of the American Thoracic Society.
[123] T. Omland,et al. Troponin T elevation and long-term mortality after chronic obstructive pulmonary disease exacerbation , 2008, European Respiratory Journal.
[124] Preeti Gupta,et al. Potential Adverse Effects of Bronchodilators in the Treatment of Airways Obstruction in Older People , 2008, Drugs & aging.
[125] Peter H Edwards,et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.
[126] Bartolome Celli,et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. , 2007, The New England journal of medicine.
[127] Robert A Wise,et al. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee , 2007, Thorax.
[128] T. Omland,et al. Statin use is associated with reduced mortality in COPD , 2006, European Respiratory Journal.
[129] J. Spertus,et al. Impact of Chronic Obstructive Pulmonary Disease on Post-Myocardial Infarction Outcomes: P201 , 2006, The American journal of cardiology.
[130] B. Celli,et al. Systemic cytokines, clinical and physiological changes in patients hospitalized for exacerbation of COPD. , 2007, Chest.
[131] N. Anthonisen,et al. Mortality in COPD: role of comorbidities , 2006, European Respiratory Journal.
[132] M. Meysman. Angiotensin II blockers in obstructive pulmonary disease: a randomised controlled trial , 2006, European Respiratory Journal.
[133] G. Ferguson,et al. Why does the lung hyperinflate? , 2006, Proceedings of the American Thoracic Society.
[134] D. Mannino,et al. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. , 2006, Respiratory medicine.
[135] Judith K Jones,et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. , 2006, Annals of epidemiology.
[136] S. Sidney,et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. , 2005, Chest.
[137] D. Kass,et al. Mechanisms, pathophysiology, and therapy of arterial stiffness. , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[138] K. Davis,et al. Trends and Cardiovascular Co-morbidities of COPD Patients in the Veterans Administration Medical System, 1991–1999 , 2005, COPD.
[139] S. Rennard. Clinical approach to patients with chronic obstructive pulmonary disease and cardiovascular disease. , 2005, Proceedings of the American Thoracic Society.
[140] E. Salpeter,et al. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. , 2004, Chest.
[141] S. Rennard. Looking at the patient--approaching the problem of COPD. , 2004, The New England journal of medicine.
[142] Don D. Sin,et al. Why Are Patients With Chronic Obstructive Pulmonary Disease at Increased Risk of Cardiovascular Diseases?: The Potential Role of Systemic Inflammation in Chronic Obstructive Pulmonary Disease , 2003 .
[143] P. Libby. Inflammation in atherosclerosis , 2002, Nature.
[144] S. Quintana,et al. Mortality after hospitalization for COPD. , 2002, Chest.
[145] D. Sin,et al. The impact of chronic obstructive pulmonary disease on work loss in the United States. , 2002, American journal of respiratory and critical care medicine.
[146] H. Folgering,et al. Discontinuation of furosemide decreases PaCO(2) in patients with COPD. , 2002, Chest.
[147] M. Alifano,et al. Abnormalities of renal endothelin during acute exacerbation in chronic obstructive pulmonary disease. , 2001, Pulmonary pharmacology & therapeutics.
[148] T. Seemungal,et al. Acute Exacerbations of Chronic Obstructive Pulmonary Disease Are Accompanied by Elevations of Plasma Fibrinogen and Serum IL-6 Levels , 2000, Thrombosis and Haemostasis.
[149] L. Shekerdemian,et al. Cardiovascular effects of mechanical ventilation , 1999, Archives of disease in childhood.
[150] M. Shipley,et al. Breathlessness, chronic bronchitis and reduced pulmonary function as predictors of cardiovascular disease mortality among men in England, Scotland and the United States. , 1989, International journal of epidemiology.
[151] K L Ebi-Kryston,et al. Respiratory symptoms and pulmonary function as predictors of 10-year mortality from respiratory disease, cardiovascular disease, and all causes in the Whitehall Study. , 1988, Journal of clinical epidemiology.
[152] R. Light,et al. Serial pulmonary function in patients with acute heart failure. , 1983, Archives of internal medicine.
[153] A. Siegelaub,et al. Lung function and risk of myocardial infarction and sudden cardiac death. , 1976, The New England journal of medicine.